CEL-SCI: Multikine can be effective in extending life for head & neck cancer

CEL-SCI announced new data from a biomarker analysis of its pivotal Phase 3 study in newly diagnosed locally advanced squamous cell carcinoma of the head and neck or SCCHN, at the American Head and Neck Cancer Society’s AHNS 11th Annual International Conference on Head and Neck Cancer on July 10 in Montreal, Canada, in the presentation titled “Tumor cell PD-L1 biomarker confirms Leukocyte Interleukin Injection treatment survival outcome advantage in naive locally advanced primary head & neck squamous cell carcinoma , the IT-MATTERS Study”. The Leukocyte Interleukin injection talk, was delivered by Philip Lavin, PhD, lead biostatistician for over 80 regulatory approvals/clearances who has also served on multiple U.S. Food and Drug Administration review panels. “This data is of great interest in that, in our opinion, they suggest Multikine can be effective in extending life in patients who are generally not well served by checkpoint inhibitors. A combination of Multikine and drugs like Keytruda or Opdivo may in fact extend the reach of coverage in this hard-to-treat disease and thus help more patients, indicating a promising new treatment path,” stated CEL-SCI CEO Geert Kersten. “Our immediate opportunity is in head and neck cancer, yet these latest results also point to potential in other solid tumors as well. We are interested in running such combination studies.” The AHNS presentation focused on